April 15, 2014 | Certara, a large CRO specializing in computational modeling for drug discovery and development, announced this morning the acquisition of Synchrogenix, the world's largest regulatory writing CRO. Certara, which is itself owned by Arsenal Capital Partners, has experienced rapid growth since 2007 through a strategy of purchasing smaller CROs offering complementary services. While earlier acquisitions of Tripos, Pharsight, and Simcyp focused on building out the parent CRO's software capabilities in drug informatics and computational chemistry, Synchrogenix is the first company brought under the Certara umbrella to be primarily involved in the administrative functions of clinical trials. Synchrogenix's seven locations in North America, Europe, and Asia will be merged with Certara's global operations.